Daniel Gooch brings over twenty years of communications, policy, & public affairs experience, specialised in life sciences, with a focus on rare diseases, gene therapy and genetic testing. Daniel has utilised this extensive experience to support a wide range of US, European and Australian life sciences clients including start-ups, private and public biotech companies, pharmaceutical companies, and member associations.
Daniel helps companies craft their messages, and brand communications, for a wide range of audiences, building corporate value and enhancing reputation. Notable client experience includes Ablynx, Agendia, AmpliPhi, Astex Pharmaceuticals, Bluebird Therapeutics, Dimerix, F-Star, Forbion Capital Partners, Hookipa, Molecular Partners, Novartis, Polyganics, Prosensa, Sarepta Therapeutics, & Xellia Pharmaceuticals.
In 2010, he moved into communications and lobbying work following over a decade’s career in the UK civil service, where he covered science policy including gene therapy, genetic testing and industrial strategies.
Daniel originally trained as a fermentation development scientist in the legacy companies of Roche in Germany, and GSK in the UK, producing novel biologics for treating cancer. He has an Masters degree in Biotechnology, a First in Applied Biology, and CAM qualifications in PR, advertising and marketing.
Daniel has also supported local Government and charity work. He’s helping London’s City Hall make London the best place to do business, especially life sciences, and he has helped the voices of people with rare conditions be heard in the UK Parliament, to secure better access to medicines.